[{"address1": "10170 Church Ranch Way", "address2": "Suite 100", "city": "Westminster", "state": "CO", "zip": "80021", "country": "United States", "phone": "720 940 2200", "website": "https://www.arcabio.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.", "fullTimeEmployees": 4, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas A. Keuer", "age": 64, "title": "President, COO & Principal Executive Officer", "yearBorn": 1959, "fiscalYear": 2023, "totalPay": 400802, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. C. Jeffrey Dekker CPA", "age": 58, "title": "CFO, Treasurer & Company Secretary", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 323072, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "irWebsite": "http://phx.corporate-ir.net/phoenix.zhtml?c=109749&p=irol-irhome", "maxAge": 86400, "priceHint": 4, "previousClose": 3.63, "open": 3.61, "dayLow": 3.4101, "dayHigh": 3.65, "regularMarketPreviousClose": 3.63, "regularMarketOpen": 3.61, "regularMarketDayLow": 3.4101, "regularMarketDayHigh": 3.65, "beta": 1.205, "forwardPE": -0.39545453, "volume": 53837, "regularMarketVolume": 53837, "averageVolume": 1444029, "averageVolume10days": 267630, "averageDailyVolume10Day": 267630, "bid": 3.46, "ask": 3.51, "bidSize": 400, "askSize": 200, "marketCap": 50463828, "fiftyTwoWeekLow": 1.56, "fiftyTwoWeekHigh": 3.88, "fiftyDayAverage": 2.227, "twoHundredDayAverage": 1.9723, "currency": "USD", "enterpriseValue": 13312978, "floatShares": 5675457, "sharesOutstanding": 14501100, "sharesShort": 5662428, "sharesShortPriorMonth": 183582, "sharesShortPreviousMonthDate": 1710460800, "dateShortInterest": 1713139200, "sharesPercentSharesOut": 0.39049998, "heldPercentInsiders": 0.0128999995, "heldPercentInstitutions": 0.71803004, "shortRatio": 1.37, "shortPercentOfFloat": 0.5463, "impliedSharesOutstanding": 14501100, "bookValue": 2.553, "priceToBook": 1.3631022, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -5339000, "trailingEps": -0.37, "forwardEps": -8.8, "lastSplitFactor": "1:18", "lastSplitDate": 1554336000, "enterpriseToEbitda": -1.869, "52WeekChange": 0.74, "SandP52WeekChange": 0.21080327, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "ABIO", "underlyingSymbol": "ABIO", "shortName": "ARCA biopharma, Inc.", "longName": "ARCA biopharma, Inc.", "firstTradeDateEpochUtc": 871047000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "aefe4f03-299b-3999-a469-92fced461200", "messageBoardId": "finmb_26198824", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.48, "recommendationKey": "none", "totalCash": 37431000, "totalCashPerShare": 2.581, "ebitda": -7122000, "totalDebt": 280000, "quickRatio": 58.761, "currentRatio": 59.014, "debtToEquity": 0.756, "returnOnAssets": -0.11021, "returnOnEquity": -0.13569, "freeCashflow": -4141625, "operatingCashflow": -5014000, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-26"}]